Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024
Resverlogix Corp. (TSX: RVX) presented at the European Society of Cardiology (ESC) Congress 2024, highlighting apabetalone's potential cardioprotective benefits. Key points include:
1. Apabetalone reduced MACE and heart failure hospitalization hazard by 63% (p=0.0002) in patients taking next-generation glucose-lowering drugs.
2. Independent researchers presented data on apabetalone's benefits for vascular dysfunction, heart failure, cellular aging, and pulmonary arterial hypertension.
3. The company positions apabetalone as a drug with potential benefits across various metabolic diseases, including cardiovascular disease, chronic kidney disease, inflammation, and diabetes.
4. Resverlogix plans to demonstrate apabetalone's efficacy in combination with SGLT2 inhibitors in the upcoming BETonMACE2 trial.
Resverlogix Corp. (TSX: RVX) ha presentato al Congresso della Società Europea di Cardiologia (ESC) 2024, mettendo in evidenza il potenziale beneficio cardioprotettivo di apabetalone. I punti chiave includono:
1. Apabetalone ha ridotto il rischio di MACE e di ospedalizzazione per insufficienza cardiaca del 63% (p=0.0002) nei pazienti che assumono farmaci per abbassare la glicemia di nuova generazione.
2. Ricercatori indipendenti hanno presentato dati sui benefici di apabetalone per la disfunzione vascolare, l'insufficienza cardiaca, l'invecchiamento cellulare e l'ipertensione arteriosa polmonare.
3. L'azienda posiziona apabetalone come un farmaco con potenziali benefici in varie malattie metaboliche, tra cui malattie cardiovascolari, malattie renali croniche, infiammazione e diabete.
4. Resverlogix prevede di dimostrare l'efficacia di apabetalone in combinazione con inibitori SGLT2 nel prossimo studio BETonMACE2.
Resverlogix Corp. (TSX: RVX) presentó en el Congreso de la Sociedad Europea de Cardiología (ESC) 2024, destacando los posibles beneficios cardioprotectores de apabetalone. Los puntos clave incluyen:
1. Apabetalone redujo el riesgo de MACE y las hospitalizaciones por insuficiencia cardíaca en un 63% (p=0.0002) en pacientes que toman medicamentos de próxima generación para reducir la glucosa.
2. Investigadores independientes presentaron datos sobre los beneficios de apabetalone para la disfunción vascular, la insuficiencia cardíaca, el envejecimiento celular y la hipertensión pulmonar.
3. La empresa posiciona apabetalone como un medicamento con posibles beneficios en diversas enfermedades metabólicas, incluidas las enfermedades cardiovasculares, la enfermedad renal crónica, la inflamación y la diabetes.
4. Resverlogix planea demostrar la eficacia de apabetalone en combinación con inhibidores SGLT2 en el próximo ensayo BETonMACE2.
레제버로직 코퍼레이션 (TSX: RVX)은 2024년 유럽 심장학회(ESC) 학술대회에서 아바페타론의 심장 보호 잠재력을 강조했습니다. 주요 내용은 다음과 같습니다:
1. 아바페타론은 최신형 혈당 강하제를 복용하는 환자에서 MACE와 심부전 입원 위험을 63% (p=0.0002) 줄였습니다.
2. 독립 연구자들이 아바페타론이 혈관 기능 장애, 심부전, 세포 노화 및 폐동맥 고혈압에 미치는 이점에 대한 데이터를 발표했습니다.
3. 이 회사는 아바페타론이 심혈관 질환, 만성 신장 질환, 염증 및 당뇨병을 포함한 다양한 대사 질환에서 잠재적인 이점을 가진 약물로 자리매김하고 있습니다.
4. 레제버로직은 다가오는 BETonMACE2 시험에서 SGLT2 억제제와 함께 아바페타론의 효능을 입증할 계획입니다.
Resverlogix Corp. (TSX: RVX) a présenté lors du Congrès de la Société Européenne de Cardiologie (ESC) 2024, soulignant les bénéfices cardioprotecteurs potentiels d'apabetalone. Les points clés incluent:
1. Apabetalone a réduit le risque de MACE et d'hospitalisations pour insuffisance cardiaque de 63% (p=0.0002) chez les patients prenant des médicaments hypoglycémiants de nouvelle génération.
2. Des chercheurs indépendants ont présenté des données sur les avantages d'apabetalone pour la dysfonction vasculaire, l'insuffisance cardiaque, le vieillissement cellulaire et l'hypertension artérielle pulmonaire.
3. L'entreprise positionne apabetalone comme un médicament ayant des bénéfices potentiels dans diverses maladies métaboliques, y compris les maladies cardiovasculaires, les maladies rénales chroniques, l'inflammation et le diabète.
4. Resverlogix prévoit de démontrer l'efficacité d'apabetalone en combinaison avec des inhibiteurs SGLT2 lors de l'essai BETonMACE2 à venir.
Resverlogix Corp. (TSX: RVX) hat auf dem Kongress der Europäischen Gesellschaft für Kardiologie (ESC) 2024 vorgestellt und die potenziellen kardioprotektiven Vorteile von Apabetalone hervorgehoben. Die wichtigsten Punkte sind:
1. Apabetalone reduzierte das Risiko von MACE und Krankenhausaufenthalten wegen Herzinsuffizienz um 63% (p=0.0002) bei Patienten, die Medikamente zur Senkung des Blutzuckers aus der nächsten Generation einnahmen.
2. Unabhängige Forscher präsentierten Daten zu den Vorteilen von Apabetalone bei vaskulärer Dysfunktion, Herzinsuffizienz, zellulärem Altern und pulmonaler Hypertonie.
3. Das Unternehmen positioniert Apabetalone als ein Medikament mit potenziellen Vorteilen bei verschiedenen Stoffwechselerkrankungen, einschließlich Herz-Kreislauf-Erkrankungen, chronischen Nierenerkrankungen, Entzündungen und Diabetes.
4. Resverlogix plant, die Wirksamkeit von Apabetalone in Kombination mit SGLT2-Hemmern in der bevorstehenden BETonMACE2-Studie zu demonstrieren.
- Apabetalone showed a 63% reduction in MACE and heart failure hospitalization hazard in patients taking next-generation glucose-lowering drugs
- Multiple independent research groups presented data supporting apabetalone's potential benefits
- Apabetalone's mechanism of action targets epigenetic dysregulation, a core driver of chronic disease
- Upcoming BETonMACE2 trial aims to demonstrate apabetalone's efficacy in combination with SGLT2 inhibitors
- None.
Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified
Calgary, Alberta--(Newsfile Corp. - September 3, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or "the Company") today announced its presentation at the European Society of Cardiology ("ESC") Congress 2024 in London, UK on September 1, 2024. Resverlogix's Chief Scientific Officer, Dr. Ewelina Kulikowski, gave a presentation entitled: "Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial".
"The importance of the presentations at this year's ESC congress is that they position apabetalone as a drug with potential benefits across various metabolic diseases such as cardiovascular disease, chronic kidney disease, inflammation, & diabetes," said Donald McCaffrey, President & CEO of Resverlogix. "For the past several years Resverlogix has led the way in developing a program to tackle the underlying causes of these diseases, cross treatment boundaries, and - in conjunction with other treatments - deliver real benefits for patients. We were pleased to see other groups promote this combinatorial approach at this year's ESC event."
The conference featured presentations on next-generation glucose lowering drugs, such as sodium-glucose cotransporter-2 inhibitors ("SGLT2i") and glucagon-like peptide-1 receptor agonists ("GLP-1 RA"), focused on their additional cardiovascular benefits in diabetic and chronic kidney disease ("CKD") patients. Current ESC guidelines on the treatment of cardiovascular disease in diabetic patients reports a pooled
"The data presented at the ESC Congress indicates that patients receiving the best currently available treatments still face significant risk of cardiovascular events," said Mr. McCaffrey. "Our Phase 3 results suggest that apabetalone and SGLT2 inhibitors - in combination - can further reduce the risk of events, and we believe we will conclusively demonstrate this in our upcoming BETonMACE2 trial."
In addition to Resverlogix's presentation on the benefit of apabetalone in cardiac remodeling - a key process in the prevention of heart failure, two oral presentations and two moderated posters - all submitted by independent researchers unaffiliated with the Company - featured research on apabetalone's potential benefits for vascular dysfunction, heart failure, cellular aging, and pulmonary arterial hypertension, respectively. These presentations showcased new evidence from animal models of heart failure showing positive apabetalone treatment effects, and they also provided important mechanistic insights connecting apabetalone's inhibition of bromodomain and extra-terminal domain ("BET") proteins to our clinically-observed benefits. Presentation details can be found on the ESC's scientific programme.
"We are excited to observe scientific research being presented by multiple independent groups on the potential benefits of apabetalone in the treatment of chronic disease," said Dr. Kulikowski. "This research recognizes the important role played by BET proteins in the epigenetic dysregulation that is a core driver of chronic disease. We see growing excitement around apabetalone's ability to counter this dysregulation through its epigenetic mechanism of action."
A scientific review, published online this month in Pharmacological Research, entitled: "Exploring the therapeutic potential of apabetalone in diabetic kidney disease: Bridging preclinical findings with clinical translation" also highlighted potential benefits of apabetalone for the treatment of diabetic kidney disease. The article can be found HERE.
About Apabetalone
Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes.
Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes representing a new way to treat chronic disease. Apabetalone is the only drug of its class that is well tolerated for chronic administration, with an established safety record across multiple human clinical trials, totaling over 4200 patient-years of safety data.
Cardiology:
Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food & Drug Administration for a major cardiovascular indication. This followed the ground-breaking findings from its Phase 3 study, BETonMACE, which showed apabetalone may prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.
The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.
Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).
Follow us:
- Twitter: @Resverlogix_RVX.
- LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
Forward Looking Statements:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, diabetes, chronic kidney disease, post COVID-19 conditions, pulmonary arterial hypertension, aging, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
www.resverlogix.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221933
FAQ
What was the main finding presented by Resverlogix at the ESC Congress 2024 regarding apabetalone (RVXCF)?
How does apabetalone (RVXCF) compare to SGLT2i and GLP-1 RA in terms of MACE reduction?
What is the mechanism of action of apabetalone (RVXCF) presented at the ESC Congress 2024?
What is Resverlogix's (RVXCF) next step in developing apabetalone?
